Granulocyte Colony Stimulating Factor Treatment For Croh

G-CSF在克罗恩病中的开放标签试验旨在建立安全性并研究该药物在中度活动性疾病中诱导缓解的有效性。到目前为止，我们已经在该方案中筛选了6名并入组了5名受试者。反应从完全缓解到根本没有反应。我们正在收集外周和固有层单核细胞和树突状细胞群分泌细胞因子变化的数据。我们将这些与临床参数联系起来，包括肠道炎症的生化指标。虽然目前的数据还很初步，无法给出明确的结论，但有一些有趣的趋势支持反应预测，这些预测可能会被修改，以改善未来的反应。

This open-label trial of G-CSF in Crohn's disease seeks to establish the safety and study the efficacy of this drug to induce remission in moderately active disease. We have screened 6 and enrolled 5 subjects in this protocol to date. Responses have ranged from complete remission to no response at all. We are accruing data on changes in cytokine secretion by peripheral and lamina propria mononuclear cells and dendritic cell populations. We are correlating these with clinical parameters including biochemical markers of gut inflammation. Although the data is too preliminary to present definitively at this time, there are interesting trends supporting predictors of response, predictors that could potentially be modified to improve reponse in the future.